WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 ...
- 88.5% of adult patients achieved a target lesion Physician Global Assessment (tPGA) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at Week 12 (tPGA Success), ...
Hosted on MSN
Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance
CEO Mitchell Steiner highlighted Veru's transition to a pure-play late clinical stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, following the divestiture of the ...
(RTTNews) - Alumis Inc. (ALMS), Friday has announced that it will present positive 52-week data from its Phase 2 open-label extension or OLE study of ESK-001, an oral TYK2 inhibitor, at the 2025 ...
A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without ...
Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection also linked to weight reduction. The single ascending dose trial enrolled lean ...
16don MSN
Viking outlines 52-week VANQUISH extension and plans oral VK2735 phase III start in Q4 2026
Q1 2026 Management View Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabling paths, stating, "we made significant progress with our obesity franchise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results